Erschienen in:
07.10.2021 | ASO Author Reflections
ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma
verfasst von:
Koji Kubota, MD, PhD, Akira Shimizu, MD, PhD, Yuji Soejima, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2022
Einloggen, um Zugang zu erhalten
Excerpt
Combined biomarker ratios have potential prognostic value in various cancers.
1 The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio, and fibrinogen-to-albumin ratio have been used as prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC).
2‐4 Although the usefulness of various prognostic factors has been reported, the most effective pre-operative biomarker for PDAC patients has not yet been established. Preoperative evaluation using predictors of long-term prognosis can be useful in determining the appropriate treatment for PDAC. …